Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05605093
Other study ID # S-217622
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date December 23, 2022
Est. completion date July 27, 2025

Study information

Verified date June 2024
Source University of Minnesota
Contact Cavan Reilly, PhD
Phone 612-624-9644
Email cavanr@biostat.umn.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi &; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addition to standard of care (SOC) for inpatients with COVID-19. The SOC will be determined by local established guidelines and may include additional DAA (e.g., remdesivir) and immunomodulatory treatment strategies. Certain SOC treatments will be pre-specified prior to randomization.


Recruitment information / eligibility

Status Recruiting
Enrollment 1500
Est. completion date July 27, 2025
Est. primary completion date July 27, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years. - Informed consent for trial participation. - Hospital admission (or boarding in an emergency department or other area awaiting hospital admission) with signs and/or symptoms of a respiratory infection. - Confirmation of SARS-CoV2 infection by nucleic acid test (NAT) or equivalent non- NAT test [list of approved tests is in the PIM] collected within the prior 14 days. - Onset of symptoms attributable to SARS-CoV2 infection occurred within 14 days before randomization. - Hospitalized for the management of COVID-19, with signs and/or symptoms suggestive of lower respiratory tract infection. Exclusion Criteria: - The patient is expected to be discharged from the hospital within the next 24 hours. - Medical condition other than the acute respiratory infection (and its manifestations) that is likely to result in death within 7 days of randomization. - Use of a strong CYP3A inducer within 14 days prior to enrollment - Moribund condition, defined as prior cardiac arrest during this hospitalization and life expectancy less than 48 hours of randomization. - Patient undergoing comfort care measures only such that treatment focuses on end-of- life symptom management over prolongation of life. - Expected inability or unwillingness to participate in study procedures. - In the opinion of the investigator, participation in a trial is not in the best interest of the patient. - Allergy to investigational agent or vehicle - Use of a concomitant medication that is contraindicated due to a drug-drug interaction with S-217622 - Moderate to severe hepatic impairment (i.e., Child-Pugh class B or C) or acute liver failure. - Known estimated glomerular filtration rate (eGRF) <30 mL/min/1.73m 2 - Continuous renal replacement therapy or chronic dialysis - Current pregnancy - Current breastfeeding and unwillingness to defer breastfeeding for 30 days after the last dose of investigational agent. - Women of child-bearing potential who are unwilling to abstain from sexual intercourse with men or practice appropriate contraception through 30 days from the last dose of the investigational agent. - Men who are unwilling to abstain from sexual intercourse with women of child- bearing potential or to use barrier contraception through 30 days from the last dose of the investigational agent. - Inability to take investigational agent in tablet form by mouth.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Shionogi Protease Inhibitor (S-217622)
S-217622 (ensitrelvir) is an oral anti-SARS-CoV2 PI that does not require ritonavir co-administration The dose is 375/125 (375 mg on Day 0, followed by 125 mg daily on Days 1-4).
placebo
Placebo is an oral tablet administered once (3 tabs) on Day 0 and once (1 tab) daily on days 1-4, 5-day course.

Locations

Country Name City State
Argentina Sanatorio Medico de Diagnostico y Tratamiento (611-029) Santa Fe
Australia Austin Health (612-020) Heidelberg Victoria
Australia The Alfred Hospital (Site 612-017) Melbourne Victoria
Australia St. Vincent's Hospital (Site 612-002) Sydney New South Wales
Australia Westmead Hospital (Site 612-058) Westmead New South Wales
Brazil Instituto de Infectologia Emílio Ribas - IIER (Site 649-001) Sao Paulo SP
Denmark Aalborg Hospital (Site 625-005) Aalborg
Denmark Aarhus Universitetshospital, Skejby (625-002) Aarhus N
Denmark Bispebjerg Hospital (Site 625-013) Copenhagen
Denmark Rigshospitalet, CHIP (Site 625-006) Copenhagen
Denmark Herlev/Gentofte Hospital (Site 625-012) Hellerup
Denmark Nordsjaellands Hospital, Hillerod (Site 625-009) Hillerød
Denmark Hvidovre University Hospital, Department of Infections Diseases (Site 625-001) Hvidovre
Denmark Kolding Sygehus, Medicinsk Afdeling (Site 625-011) Kolding
Denmark Odense University Hospital (Site 625-004) Odense
Denmark Zealand University Hospital Roskilde (Site 625-010) Roskilde
Georgia AIDS and Clinical Immunology Research Center (Site 627-201) Tbilisi
Germany Universitätsklinikum Bonn, Medizinische Klinik I, Immunologische Ambulanz (622-010) Bonn
Germany Klinik I für Innere Medizin der Universität zu Köln (Site 622-008) Cologne
Germany Johann Wolfgang Goethe Univ. Hosp., Infektionsambulanz CRS (622-001) Frankfurt
Greece Democritus University of Thrace (635-021) Alexandroupolis Evros
Greece 1st Respiratory Medicine Dept, Athens University Medical School (635-015) Athens Attica
Greece 3rd Dept of Medicine, Medical School (635-022) Athens Attica
Greece Attikon University General Hospital (Site 635-009) Athens Attica
Greece Dept of Critical Care and Pulmonary Medicine, Evangelismos General Hospital (635-020) Athens Attica
Japan Rinku General Medical Center (Site 612-107) Osaka
Japan Center Hospital of the National Center for Global Health and Medicine (Site 612-101) Shinjuku-Ku Tokyo
Japan Fujita Health University Hospital (Site 612-105) Toyoake Aichi
Korea, Republic of Seoul St. Mary's Hospital (Site 612-903) Seocho Seoul
Korea, Republic of Seoul National University Bundang Hospital (Site 612-904) Seongnam Gyeonggi
Korea, Republic of Asan Medical Center (612-901) Seoul
Korea, Republic of Chung-Ang University Hospital (Site 612-902) Seoul
Nigeria Institute of Human Virology-Nigeria (IHVN) (Site 612-601) Abuja FCT
Puerto Rico VA Caribbean Health Care (074-033) San Juan
Singapore Tan Tock Seng Hospital (Site 612-201) Singapore
South Africa University of Cape Town (UCT) Lung Institute (Site 080-201) Cape Town Western Cape
South Africa Durban International Clinical Research Site (WWH) (652-005) Durban KwaZulu-Natal
South Africa Greys Hospital (080-202) Pietermaritzburg KwaZulu-Natal
Spain Hospital Universitari Germans Trias i Pujol (626-003) Badalona Barcelona
Spain Hospital Clinic de Barcelona (626-004) Barcelona
Spain Hospital del Mar (626-025) Barcelona
Spain Hospital Universitari Vall d'Hebron (Site 626-033) Barcelona
Spain Hospital Clínico San Carlos (Site 626-017) Madrid
Spain Hospital General Universitario Gregorio Marañón (Site 626-001) Madrid
Spain Hospital Universitario La Paz (Site 626-012) Madrid
Thailand Chulalongkorn University and The HIV-NAT (Site 613-001) Bangkok
Thailand Khon Kaen University, Srinagarind Hospital (Site 613-003) Khon Kaen
Uganda MRC/UVRI & LSHTM Uganda Research Unit (634-601) Entebbe
Uganda Gulu Regional Referral Hospital (634-603) Gulu
Uganda St. Francis Hospital, Nsambya (Site 634-607) Kampala
Uganda Lira Regional Referral Hospital (634-605) Lira
Uganda Masaka Regional Referral Hospital (634-606) Masaka
Ukraine Central City Clinical Hospital of Ivano-Frankivsk City Council (Site 627-302) Ivano-Frankivs'k Frankivs'k
United Kingdom Royal Free Hospital (634-006) London
United Kingdom Royal Victoria Infirmary (Site 634-007) Newcastle Upon Tyne
United States Hendrick Medical Center (Site 080-014) Abilene Texas
United States University of New Mexico Hospital (Site 213-008) Albuquerque New Mexico
United States VA Ann Arbor Healthcare System (Site 074-028) Ann Arbor Michigan
United States Rocky Mountain Regional VA Medical Center (Site 074-010) Aurora Colorado
United States University of Colorado Hospital (Site 204-001) Aurora Colorado
United States NIH Clinical Center (Site 080-043) Bethesda Maryland
United States University of Alabama Birmingham University Hospital (Site 213-002) Birmingham Alabama
United States Beth Israel Deaconess Medical Center (Site 202-001) Boston Massachusetts
United States Massachusetts General Hospital (202-002) Boston Massachusetts
United States James J. Peters VAMC (Site 023-003) Bronx New York
United States Lincoln Medical Center (Site 003-016) Bronx New York
United States Montefiore Medical Center - Moses Hospital (Site 206-001) Bronx New York
United States Montefiore Medical Center - Weiler campus (Site 206-003) Bronx New York
United States NYU Brooklyn (301-033) Brooklyn New York
United States Cooper University Hospital (Site 019-001) Camden New Jersey
United States Medical University of South Carolina (Site 210-002) Charleston South Carolina
United States Ralph H. Johnson VA Medical Center (Site 074-015) Charleston South Carolina
United States University of Virginia Health System, University Hospital (Site 210-003) Charlottesville Virginia
United States University of Illinois at Chicago (Site 008-012) Chicago Illinois
United States University of Cincinnati Medical Center (Site 207-003) Cincinnati Ohio
United States Cleveland Clinic Foundation (Site 207-001) Cleveland Ohio
United States Ohio State University Wexner Medical Center (Site 207-004) Columbus Ohio
United States CHRISTUS Spohn Shoreline Hospital (Site 080-001) Corpus Christi Texas
United States Baylor, Scott and White Health (301-003) Dallas Texas
United States Parkland Health and Hospital Systems (Site 084-002) Dallas Texas
United States UT Southwestern Medical Center (Site 084-001) Dallas Texas
United States Public Health Institute at Denver Health (Site 017-004) Denver Colorado
United States Henry Ford Health System (Site 014-001) Detroit Michigan
United States Sinai-Grace Hospital (Site 205-005) Detroit Michigan
United States Duke University Hospital (Site 301-006) Durham North Carolina
United States Lutheran Medical Group (Site 301-010) Fort Wayne Indiana
United States UCSF Fresno (Site 203-005) Fresno California
United States University of Florida - Gainesville (Site 201-004) Gainesville Florida
United States Penn State Health Milton S. Hershey Medical Center (Site 209-002) Hershey Pennsylvania
United States Houston Methodist Hospital (Site 301-028) Houston Texas
United States MEDVAMC (Site 074-006) Houston Texas
United States University of Texas Health Science Center (Site 203-006) Houston Texas
United States University of Mississippi Medical Center (Site 202-005) Jackson Mississippi
United States The University of Kansas Hospital (Site 080-044) Kansas City Kansas
United States Dartmouth-Hitchcock Medical Center (301-024) Lebanon New Hampshire
United States University of Kentucky (Site 210-004) Lexington Kentucky
United States VA Loma Linda Healthcare System (Site 074-017) Loma Linda California
United States MemorialCare Health System (Site 066-003 Long Beach California
United States VA Long Beach Healthcare System (Site 074-026) Long Beach California
United States Mount Sinai Queens (Site 081-105) Long Island City New York
United States CHRISTUS Good Shepherd Medical Center (Site 080-031) Longview Texas
United States Cedars-Sinai Medical Center (Site 208-002) Los Angeles California
United States Ronald Reagan UCLA Medical Center (Site 203-002) Los Angeles California
United States William S. Middleton Memorial Veterans Hospital (074-030) Madison Wisconsin
United States VA Northern California Health Care System (Site 074-023) Mather California
United States Froedtert Memorial Lutheran Hospital (052-001) Milwaukee Wisconsin
United States NYU Long Island (301-034) Mineola New York
United States Hennepin Healthcare Research Institute (Site 027-001) Minneapolis Minnesota
United States M Health Fairview University of Minnesota Medical Center (Site 112-001) Minneapolis Minnesota
United States University of Minnesota Minneapolis Minnesota
United States West Virginia University Medicine Morgantown West Virginia
United States Intermountain Medical Center (Site 211-001) Murray Utah
United States Vanderbilt University Medical Center (Site 212-001) Nashville Tennessee
United States Yale University (Site 025-001) New Haven Connecticut
United States Mount Sinai Medical Center (Site 301-012) New York New York
United States New York University Tisch Hospital (Site 301-013) New York New York
United States NYC Health + Hospital Harlem (Site 003-003) New York New York
United States Weill Cornell Clinical Research Unit (065-001) New York New York
United States New Jersey Medical School Clinical Research Center (028-001) Newark New Jersey
United States Hoag Memorial Hospital Presbyterian (Site 080-026) Newport Beach California
United States University of Nebraska Medical Center (Site 080-045) Omaha Nebraska
United States Orlando VA Medical Center (Site 074-032) Orlando Florida
United States Veterans Affairs Palo Alto Health Care System (VAPAHCS) (Site 074-005) Palo Alto California
United States Portland VA Health Care System (074-024) Portland Oregon
United States St. Lawrence Health System (Site 301-029) Potsdam New York
United States Rhode Island Hospital (Site 080-036) Providence Rhode Island
United States The Miriam Hospital (Site 080-039) Providence Rhode Island
United States Monument Health Rapid City Hospital (Site 213-005) Rapid City South Dakota
United States Mayo Clinic (Site 054-001) Rochester Minnesota
United States UC Davis Health (Site 203-004) Sacramento California
United States Washington University School of Medicine (Site 003-001) Saint Louis Missouri
United States Salem VA Medical Center (Site 074-014) Salem Virginia
United States University of Utah Health (Site 211-002) Salt Lake City Utah
United States UT Health San Antonio (Site 009-022) San Antonio Texas
United States VA San Diego Healthcare System (Site 074-016) San Diego California
United States San Francisco VAMC (Site 074-002) San Francisco California
United States UCSF Medical Center at Mount Zion (203-007) San Francisco California
United States University of California San Francisco (Site 203-001) San Francisco California
United States Zuckerberg San Francisco General Hospital and Trauma Center (Site 213-007) San Francisco California
United States CHRISTUS - St. Vincent (Site 080-051) Santa Fe New Mexico
United States Harborview Medical Center (208-001) Seattle Washington
United States Providence (Sacred Heart) (Site 213-004) Spokane Washington
United States Baystate Medical Center (Site 201-001) Springfield Massachusetts
United States Stanford University Hospital & Clinics (Site 203-003) Stanford California
United States Tampa General Hospital (032-001) Tampa Florida
United States Lundquist Institute for Biomedical Innovation (Site 066-002) Torrance California
United States Banner University Medical Center Tucson (Site 206-004) Tucson Arizona
United States Southern Arizona VA Healthcare System (Site 074-009) Tucson Arizona
United States Carle Foundation Hospital (Site 080-049) Urbana Illinois
United States Kent County Memorial Hospital (080-048) Warwick Rhode Island
United States MedStar Health Research Institute/MedStar Washington Hospital Center (Site 009-021) Washington District of Columbia
United States Washington DC VA Medical Center (Site 009-004) Washington District of Columbia
United States Wake Forest Baptist Health (Site 210-001) Winston-Salem North Carolina
United States UMass Chan Medical School (Site 080-007) Worcester Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
University of Minnesota National Institute of Allergy and Infectious Diseases (NIAID)

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Brazil,  Denmark,  Georgia,  Germany,  Greece,  Japan,  Korea, Republic of,  Nigeria,  Puerto Rico,  Singapore,  South Africa,  Spain,  Thailand,  Uganda,  Ukraine,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Days to Recovery Scale assessed over 60 days (DRS-60) DRS-60 is a version of the STRIVE clinical recovery scale (CRS) which combines time to recovery with non-recovered clinical state and death to an ordinal outcome.0 indicates best results, 60 represents recovered on Day 60, with not recovered by Day 60 coded as 61 and death (worst outcome) as 62. 60 days post-intervention
Secondary mortality proportion of participants who died by Day 60 60 days post-treatment
Secondary a 3-category ordinal outcome the following categories: recovered (alive and at home at Day 60), alive and not recovered, and dead 60 days post-treatment
Secondary time to recovery 60 days post-treatment
Secondary proportion of participants who died or required new invasive mechanical ventilation 60 days post-treatment
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure